PT  - JOURNAL ARTICLE
AU  - Marah G. Chibwana
AU  - Khuzwayo C. Jere
AU  - Raphael Kamn’gona
AU  - Jonathan Mandolo
AU  - Vincent Katunga-Phiri
AU  - Dumizulu Tembo
AU  - Ndaona Mitole
AU  - Samantha Musasa
AU  - Simon Sichone
AU  - Agness Lakudzala
AU  - Lusako Sibale
AU  - Prisca Matambo
AU  - Innocent Kadwala
AU  - Rachel L. Byrne
AU  - Alice Mbewe
AU  - Marc Y. R. Henrion
AU  - Ben Morton
AU  - Chimota Phiri
AU  - Jane Mallewa
AU  - Henry C Mwandumba
AU  - Emily R. Adams
AU  - Stephen B. Gordon
AU  - Kondwani C. Jambo
TI  - High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi
AID  - 10.1101/2020.07.30.20164970
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.30.20164970
4099  - http://medrxiv.org/content/early/2020/08/05/2020.07.30.20164970.short
4100  - http://medrxiv.org/content/early/2020/08/05/2020.07.30.20164970.full
AB  - Background In low-income countries, like Malawi, important public health measures including social distancing or a lockdown have been challenging to implement owing to socioeconomic constraints, leading to predictions that the COVID-19 pandemic would progress rapidly. However, due to limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there are no reliable estimates of the true burden of infection and death. We, therefore, conducted a SARS-CoV-2 serosurvey amongst health care workers (HCWs) in Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection in urban Malawi.Methods We recruited 500 otherwise asymptomatic HCWs from Blantyre City (Malawi) from 22nd May 2020 to 19th June 2020 and serum samples were collected from all participants. A commercial ELISA was used to measure SARS-CoV-2 IgG antibodies in serum.Results A total of 84 participants tested positive for SARS-CoV-2 antibodies. The HCWs with positive SARS-CoV-2 antibody results came from different parts of the city. The adjusted seroprevalence of SARS-CoV-2 antibodies was 12.3% [CI 8.2 - 16.5]. Using age-stratified infection fatality estimates reported from elsewhere, we found that at the observed adjusted seroprevalence, the number of predicted deaths was eight times the number of reported deaths.Conclusions The high seroprevalence of SARS-CoV-2 antibodies among HCWs and the discrepancy in the predicted versus reported deaths suggests that there was early exposure but slow progression of COVID-19 epidemic in urban Malawi. This highlights the urgent need for development of locally parameterised mathematical models to more accurately predict the trajectory of the epidemic in sub-Saharan Africa for better evidence-based policy decisions and public health response planning.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust through a Wellcome Training Fellowship [201945; to K.C.J], the Wellcome Trust/DFID Joint Initiative for Research in Epidemic Preparedness and Response [220764; to E.R.A] and the Malawi-Liverpool-Wellcome Trust Clinical Research Programme [MLW] was supported by a strategic award from the Wellcome Trust awarded to S.B.G. K.C.J was also supported by the NIHR and MRC through grant numbers 3477609 and MR/T008822/1, respectively. M.G.C. is supported by NIH through grant number U01AI131348. E.R.A is also supported by the NIHR HPRU [200907] in Emerging and Zoonotic Infection.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:College of Medicine Research and Ethics Committee (COMREC, Malawi) (P.05/20/3045) Liverpool School of Tropical Medicine (LSTM, UK) (20-043).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on Figshare: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. This project contains the following underlying data: - PROTECT_FigShare Part 1 31072020.csv - PROTECT_screening_enrolment_data_dictionary Figshare 31072020.pdf Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). https://doi.org/10.6084/m9.figshare.12745214.v2